Boston Scientific Announces Acquisition Of nVision Medical Corporation

Boston Scientific Corporation, a $8.83b manufacturer of medical devices for cardiovascular, digestive, pulmonary and other interventional specialties is acquiring nVision Medical, a developer of a device for collecting cells from the fallopian tubes to detect ovarian cancer. Ovarian cancer is the fifth leading cause of cancer death among women. More than 2 million women in the U.S. are at high risk and it occurs more frequently in those with a family history or with gene mutations. There are no recommended early screening tests and, to date, there has been no effective way to biopsy cells in the fallopian tubes. Boston estimates the market to be $500m with the potential to grow to $2b as this device is used by more gynecologists to help even more women. nVision devices effectively collects cells which, when tested, correlate with a post-surgery definitive diagnosis of ovarian cancer. Boston Scientific plans to conduct additional clinical research with the nVision device to further establish how the cells it collects from the fallopian tubes can be used to render a diagnosis prior to surgery and help in the decision-making process for women at increased risk for ovarian cancer. Deal value -- $150m plus and additional milestone of $125m

Keywords: Healthcare Investment Banking, Healthcare M&A, Healthcare mergers